This study reveals binding interactions in schizophrenia treatment using hydroxytetrahydroxanthes, suggesting further research into dopamine D2 receptor antagonists.
Schizophrenia poses a substantial mental health challenge, affecting 5 individuals per thousand. The prevalence of this serious mental illness emphasizes the imperative need for ongoing research. In this study, authors have explored the therapeutic potential of a library of previously synthesized xanthene analogues by their research group as antagonists of the dopamine D2 receptor (D2R) in the context of neuropsychiatric conditions such as schizophrenia and Parkinson's disease. All the molecules were docked against the dopamine D2 receptor using Auto Dock vina. Based on the binding energy obtained, it can be seen that AR28 shows the best binding affinity (i.e., ‐11.5 kcal/mol) and also forms a stable complex. ADMET experiments assessed pharmacokinetics and safety, while computational models evaluated lipophilicity, solubility, and drug‐likeness. DFT calculations provided insights into electrical characteristics, stability, reactivity, and potential biological activities. From molecular dynamic simulations, it was found that the complexes were stable over time. For AR28 ΔG obtained from MMGBSA was found to be −82.34 kcal/mol. Our findings collectively highlight the promising inhibitory potential of these xanthene analogues against D2R activity, with the results from molecular docking, molecular simulation, ADMET investigations, and DFT simulations offering comprehensive insights into their binding interactions, pharmacokinetic parameters, and electronic properties.
No takes yet. Share an insight, caveat, or question.
Rani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: